share_log

泽璟制药:盐酸吉卡昔替尼片获II/III期临床试验批准

Zejing Pharmaceutical: Gicaxitinib hydrochloride tablets approved for phase II/III clinical trials

Breakings ·  May 29 16:04
Zejing Pharmaceutical announced that the phase II/III clinical trial of the company's self-developed gicaxitinib hydrochloride tablets (formerly known as jacketinib hydrochloride tablets) to treat adolescents and adults aged 12 and above with non-segmental vitiligo was approved by the State Drug Administration. This drug is a class 1 new drug. The company has independent intellectual property rights. It has a significant inhibitory effect on Janus kinase, blocks the JAK-STAT signaling pathway, and improves iron metabolism imbalance. Currently, the drug is undergoing clinical research on a number of immunoinflammatory diseases and fibrosis diseases, and research to treat myelofibrosis has received support from the national “Major New Drug Creation” science and technology project. This approval will not have a significant impact on the company's recent performance, but there are uncertainties due to the long drug development cycle, many approval processes, and large R&D investment. Investors are kindly requested to be aware of the risks.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment